Intellia Therapeutics

Intellia Therapeutics

Focus:

Type: Startup
Founded: 2014


Our researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. We at Intellia are humbled to have a hand in making what we believe to be medical history. As a leader in this space, we take this responsibility to patients seriously.

We are employing a modular genome editing platform to create diverse in vivo and ex vivo pipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, we are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.


Leadership
Andy May
Founder (not involved anymore)

Derrick Rossi
Founder (not involved anymore)

Erik Sontheimer
Founder (not involved anymore)

Jennifer Doudna
Founder (not involved anymore)
Past Roles
Founder (Intellia Therapeutics)
Founder (Editas Medicine)

Luciano Marraffini
Founder (not involved anymore)

Nessan Bermingham
Founder (not involved anymore)

Rodolphe Barrangou
Founder


Funding


Raised Capital
Year
Type
Offered / Sold Amount
Filings
Reported by Press*
Round
2014
15M USD
Series A
2015
70.0 / 70.0M USD
70M USD
Series B
2016
108M USD
Post-IPO Equity
Known Investors
Name
Type
HQ
Other Relevant Investments
Venture Capital
United States
Venture Capital
United States
Investment Bank
United States
Venture Capital
United States
Asset Management
United States
Corporate Venture
Switzerland
Venture Capital
United States
Asset Management
Canada
*More data available at: [CB Insights] [CrunchBase] [PitchBook]

Related
News